1. Selective SERCA2a activator as a candidate for chronic heart failure therapy
- Author
-
Arici, M, Hsu, S, Ferrandi, M, Barassi, P, Ronchi, C, Torre, E, Luraghi, A, Chang, G, Ferrari, P, Bianchi, G, Peri, F, Zaza, A, Rocchetti, M, Arici, Martina, Hsu, Shih-Che, Ferrandi, Mara, Barassi, Paolo, Ronchi, Carlotta, Torre, Eleonora, Luraghi, Andrea, Chang, Gwo-Jyh, Ferrari, Patrizia, Bianchi, Giuseppe, Peri, Francesco, Zaza, Antonio, Rocchetti, Marcella, Arici, M, Hsu, S, Ferrandi, M, Barassi, P, Ronchi, C, Torre, E, Luraghi, A, Chang, G, Ferrari, P, Bianchi, G, Peri, F, Zaza, A, Rocchetti, M, Arici, Martina, Hsu, Shih-Che, Ferrandi, Mara, Barassi, Paolo, Ronchi, Carlotta, Torre, Eleonora, Luraghi, Andrea, Chang, Gwo-Jyh, Ferrari, Patrizia, Bianchi, Giuseppe, Peri, Francesco, Zaza, Antonio, and Rocchetti, Marcella
- Abstract
Background: The sarcoplasmic reticulum (SR) Ca2+ ATPase (SERCA2a) depression substantially contributes to diastolic dysfunction in heart failure (HF), suggesting that SERCA2a stimulation may be a mechanism-based HF therapy. Istaroxime is a drug endowed with both a SERCA2a stimulatory activity and a Na+/K+ pump inhibitory activity for acute HF treatment. Its main metabolite PST3093 shows a more favorable therapeutic profile as compared to the parent drug, but it is still unsuitable for chronic usage. Novel PST3093 derivatives have been recently developed for oral (chronic) HF treatment; compound 8 was selected among them and here characterized. Methods: Effects of compound 8 were evaluated in a context of SERCA2a depression, by using streptozotocin-treated rats, a well-known model of diastolic dysfunction. The impact of SERCA2a stimulation by compound 8 was assessed at the cellular level ad in vivo, following i.v. infusion (acute effects) or oral administration (chronic effects). Results: As expected from SERCA2a stimulation, compound 8 induced SR Ca2+ compartmentalization in STZ myocytes. In-vivo echocardiographic analysis during i.v. infusion and after repeated oral administration of compound 8, detected a significant improvement of diastolic function. Moreover, compound 8 did not affect electrical activity of healthy guinea-pig myocytes, in line with the absence of off-target effects. Finally, compound 8 was well tolerated in mice with no evidence of acute toxicity. Conclusions: The pharmacological evaluation of compound 8 indicates that it may be a safe and selective drug for a mechanism-based treatment of chronic HF by restoring SERCA2a activity.
- Published
- 2024